100 related articles for article (PubMed ID: 16984387)
61. AML1-ETO positive AML: first report from India.
Dutta P; Hasan SK; Sazawal S; Kumar B; Bhattacharyya J; Jain M; Tyagi S; Kumar R; Pati HP; Saxena R
Indian J Pathol Microbiol; 2007 Jul; 50(3):652-4. PubMed ID: 17883173
[TBL] [Abstract][Full Text] [Related]
62. Vascular density in childhood acute lymphoblastic leukaemia correlates to biological factors and outcome.
Norén-Nyström U; Heyman M; Frisk P; Golovleva I; Sundström C; Porwit A; Roos G; Bergh A; Forestier E
Br J Haematol; 2009 Sep; 146(5):521-30. PubMed ID: 19594745
[TBL] [Abstract][Full Text] [Related]
63. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation.
Balkhi MY; Christopeit M; Chen Y; Geletu M; Behre G
Exp Hematol; 2008 Nov; 36(11):1449-60. PubMed ID: 18687517
[TBL] [Abstract][Full Text] [Related]
64. Presenting features of 201 children with acute lymphoblastic leukemia: comparison according to presence or absence of ETV6/RUNX1 rearrangement.
Alvarez Y; Caballín MR; Gaitán S; Pérez A; Bastida P; Ortega JJ; Cervera J; Verdeguer A; Tasso M; Aventín A; Badell I; Guitart M; Melo M; Granada I; Javier G; Dastugue N; Robert A; Coll MD
Cancer Genet Cytogenet; 2007 Sep; 177(2):161-3. PubMed ID: 17854676
[No Abstract] [Full Text] [Related]
65. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
[TBL] [Abstract][Full Text] [Related]
66. Characterisation of genomic translocation breakpoints and identification of an alternative TCF3/PBX1 fusion transcript in t(1;19)(q23;p13)-positive acute lymphoblastic leukaemias.
Paulsson K; Jonson T; Ora I; Olofsson T; Panagopoulos I; Johansson B
Br J Haematol; 2007 Jul; 138(2):196-201. PubMed ID: 17593026
[TBL] [Abstract][Full Text] [Related]
67. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
68. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
Barry E; DeAngelo DJ; Neuberg D; Stevenson K; Loh ML; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin M; Cohen HJ; Sallan SE; Silverman LB
J Clin Oncol; 2007 Mar; 25(7):813-9. PubMed ID: 17327603
[TBL] [Abstract][Full Text] [Related]
69. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma.
Compagno M; Mantoan B; Astolfi M; Boccadoro M; Ladetto M
Methods Mol Med; 2005; 113():145-63. PubMed ID: 15968100
[TBL] [Abstract][Full Text] [Related]
70. Quantitative PCR based minimal residual disease detection in core binding factor leukemias: prognostication and guiding of therapy.
Schnittger S; Schoch C
Leuk Res; 2006 Jun; 30(6):657-8. PubMed ID: 16386301
[No Abstract] [Full Text] [Related]
71. Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease--a study within the Europe Against Cancer Program.
van der Velden VH; Boeckx N; Gonzalez M; Malec M; Barbany G; Lion T; Gottardi E; Pallisgaard N; Beillard E; Hop WC; Hoogeveen PG; Gabert J; van Dongen JJ;
Leukemia; 2004 Apr; 18(4):884-6. PubMed ID: 14961029
[No Abstract] [Full Text] [Related]
72. Minimal residual disease detection by flow cytometry.
Ludwig WD
Lab Hematol; 2004; 10(3):169. PubMed ID: 15529435
[No Abstract] [Full Text] [Related]
73. Biological microbeads for flow-cytometric immunoassays, enzyme titrations, and quantitative PCR.
Pataki J; Szabó M; Lantos E; Székvölgyi L; Molnár M; Hegedüs E; Bacsó Z; Kappelmayer J; Lustyik G; Szabó G
Cytometry A; 2005 Nov; 68(1):45-52. PubMed ID: 16163684
[TBL] [Abstract][Full Text] [Related]
74. Minimal residual disease detection in myeloma: no more molecular remissions?
Rawstron AC
Haematologica; 2005 Oct; 90(10):1300B. PubMed ID: 16219557
[No Abstract] [Full Text] [Related]
75. Improvement of gene expression analysis by RQ-PCR technology: addition of BSA.
Silvy M; Pic G; Gabert J; Picard C
Leukemia; 2004 May; 18(5):1022-5. PubMed ID: 15014530
[No Abstract] [Full Text] [Related]
76. Patient-Specific Minimal Residual Disease Primers Amplify with Uniformly High Efficiency.
Latham S; Hughes E; Budgen B; Bartley P; Morley AA
J Mol Diagn; 2021 Mar; 23(3):341-346. PubMed ID: 33359070
[TBL] [Abstract][Full Text] [Related]
77. Molecular diagnostics of lymphoma: coming of age.
Sudoyo AW
Acta Med Indones; 2006; 38(2):65-6. PubMed ID: 16812937
[No Abstract] [Full Text] [Related]
78. Atypical basophilia.
Boiten HJ; de Jongh E
Blood; 2018 Aug; 132(5):551. PubMed ID: 30072416
[No Abstract] [Full Text] [Related]
79. The polymerase chain reaction, so simple, so clever: the discovery that made minimal residual disease come true.
Cavé H
Haematologica; 2022 Aug; 107(8):1737-1738. PubMed ID: 35912723
[No Abstract] [Full Text] [Related]
80. Resolution of ambiguous low-level positive quantitative polymerase chain reaction results in TEL-AML1 positive ALL using a post-PCR fluorescent oligoligation method.
Chen IM; Chakerian A; Devidas M; Borowitz MJ; Hunger SP; Willman CL; Viswanatha DS
Br J Haematol; 2006 Nov; 135(3):358-61. PubMed ID: 16984387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
